1222. Risk Factors and Outcomes for Daptomycin Nonsusceptible Methicillin-Resistant Staphylococcus aureus Bloodstream Infections

BACKGROUND: Daptomycin (dap) has been approved and successfully used for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. However, reports of daptomycin nonsusceptible (DNS) MRSA strains have emerged over the recent years. This study describes the clinical characterist...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Open Forum Infect Dis
Autors principals: Hadid, Hind, Rizvi, Hira, Misikir, Helina, Baratz, Nathalie, Bardossy, Ana Cecilia, Sundaram, Ayesha, Haddad, Lillian, Perri, Mary Beth, Zervos, Marcus, Herc, Erica
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6253196/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.1055
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars